Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 2- year multicenter retrospective study

Name: Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 2- year multicenter retrospective study
Creator: Jihad Abou Ali Waked
Published: 2026-09-24T23:06:58.441Z
Keywords: Medicine, Dermatology

Abou Ali Waked, Jihad

doi:10.17632/93w4jd64t6.1

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 2- year multicenter retrospective study

Published: 24 September 2026| Version 1 | DOI: 10.17632/93w4jd64t6.1

Contributor:

Jihad Abou Ali Waked

Description

Bimekizumab is a novel interleukin (IL)-17A/IL-17F inhibitor approved for adult plaque psoriasis. Open-label extension (OLE) studies have evaluated long-term bimekizumab efficacy and safety, but real-world data beyond 1 year remain limited. Expanding on our prior 16- and 52-week data, this study reports 2-year real-world outcomes.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 2- year multicenter retrospective study

Description

Files

Categories

Licence